NGLFINE Stock Overview
Manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
NGL Fine-Chem Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,808.65 |
| 52 Week High | ₹2,823.90 |
| 52 Week Low | ₹1,702.35 |
| Beta | 1.13 |
| 1 Month Change | -0.90% |
| 3 Month Change | -10.44% |
| 1 Year Change | -18.91% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -3.23% |
Recent News & Updates
Recent updates
NGL Fine-Chem's (NSE:NGLFINE) Promising Earnings May Rest On Soft Foundations
May 28
NGL Fine-Chem Limited's (NSE:NGLFINE) 26% Price Boost Is Out Of Tune With Earnings
Apr 20NGL Fine-Chem Limited (NSE:NGLFINE) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Nov 18Weak Statutory Earnings May Not Tell The Whole Story For NGL Fine-Chem (NSE:NGLFINE)
Nov 05Shareholder Returns
| NGLFINE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -11.3% | 1.7% | 0.2% |
| 1Y | -18.9% | 39.1% | 17.2% |
Return vs Industry: NGLFINE underperformed the Indian Pharmaceuticals industry which returned 39.1% over the past year.
Return vs Market: NGLFINE underperformed the Indian Market which returned 17.2% over the past year.
Price Volatility
| NGLFINE volatility | |
|---|---|
| NGLFINE Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: NGLFINE has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: NGLFINE's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 682 | Rahul Nachane | www.nglfinechem.com |
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. The company offers animal health pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine hcl, s-methoprene, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, carprofen, fenbendazole, and xylazine hydrochloride. It also offers human health pharmaceutical ingredients comprising of nitazoxanide and atovaquone; and intermediates and specialty chemicals consisting of trimethyl, triazacylononane, and ethyl glucamine.
NGL Fine-Chem Limited Fundamentals Summary
| NGLFINE fundamental statistics | |
|---|---|
| Market cap | ₹11.21b |
| Earnings (TTM) | ₹413.64m |
| Revenue (TTM) | ₹3.72b |
27.1x
P/E Ratio3.0x
P/S RatioIs NGLFINE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGLFINE income statement (TTM) | |
|---|---|
| Revenue | ₹3.72b |
| Cost of Revenue | ₹1.90b |
| Gross Profit | ₹1.81b |
| Other Expenses | ₹1.40b |
| Earnings | ₹413.64m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 66.95 |
| Gross Margin | 48.80% |
| Net Profit Margin | 11.13% |
| Debt/Equity Ratio | 17.6% |
How did NGLFINE perform over the long term?
See historical performance and comparisonDividends
0.1%
Current Dividend Yield3%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 06:16 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NGL Fine-Chem Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |
| Harini V. | FirstCall Research |